167 related articles for article (PubMed ID: 16570914)
1. Identification of potent and selective inhibitors of PDGF receptor autophosphorylation.
Furuta T; Sakai T; Senga T; Osawa T; Kubo K; Shimizu T; Suzuki R; Yoshino T; Endo M; Miwa A
J Med Chem; 2006 Apr; 49(7):2186-92. PubMed ID: 16570914
[TBL] [Abstract][Full Text] [Related]
2. Identification of 4-piperazin-1-yl-quinazoline template based aryl and benzyl thioureas as potent, selective, and orally bioavailable inhibitors of platelet-derived growth factor (PDGF) receptor.
Heath JA; Mehrotra MM; Chi S; Yu JC; Hutchaleelaha A; Hollenbach SJ; Giese NA; Scarborough RM; Pandey A
Bioorg Med Chem Lett; 2004 Oct; 14(19):4867-72. PubMed ID: 15341941
[TBL] [Abstract][Full Text] [Related]
3. Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. 3. Replacement of quinazoline moiety and improvement of metabolic polymorphism of 4-[4-(N-substituted (thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline derivatives.
Matsuno K; Ushiki J; Seishi T; Ichimura M; Giese NA; Yu JC; Takahashi S; Oda S; Nomoto Y
J Med Chem; 2003 Nov; 46(23):4910-25. PubMed ID: 14584942
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of N-aryl-N'-[2-phenyl-3-quinazoline(3H)-4-one] acylthiourea derivatives as anticonvulsants.
Misra VS; Pandey RN; Dua PR
Pol J Pharmacol Pharm; 1979; 31(2):161-7. PubMed ID: 493181
[TBL] [Abstract][Full Text] [Related]
5. Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. 1. Synthesis, structure-activity relationship, and biological effects of a new class of quinazoline derivatives.
Matsuno K; Ichimura M; Nakajima T; Tahara K; Fujiwara S; Kase H; Ushiki J; Giese NA; Pandey A; Scarborough RM; Lokker NA; Yu JC; Irie J; Tsukuda E; Ide S; Oda S; Nomoto Y
J Med Chem; 2002 Jul; 45(14):3057-66. PubMed ID: 12086491
[TBL] [Abstract][Full Text] [Related]
6. Studies on disease-modifying antirheumatic drugs: synthesis of novel quinoline and quinazoline derivatives and their anti-inflammatory effect.
Baba A; Kawamura N; Makino H; Ohta Y; Taketomi S; Sohda T
J Med Chem; 1996 Dec; 39(26):5176-82. PubMed ID: 8978845
[TBL] [Abstract][Full Text] [Related]
7. Discovery of aryl aminoquinazoline pyridones as potent, selective, and orally efficacious inhibitors of receptor tyrosine kinase c-Kit.
Hu E; Tasker A; White RD; Kunz RK; Human J; Chen N; Bürli R; Hungate R; Novak P; Itano A; Zhang X; Yu V; Nguyen Y; Tudor Y; Plant M; Flynn S; Xu Y; Meagher KL; Whittington DA; Ng GY
J Med Chem; 2008 Jun; 51(11):3065-8. PubMed ID: 18447379
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor.
Palmer BD; Smaill JB; Boyd M; Boschelli DH; Doherty AM; Hamby JM; Khatana SS; Kramer JB; Kraker AJ; Panek RL; Lu GH; Dahring TK; Winters RT; Showalter HD; Denny WA
J Med Chem; 1998 Dec; 41(27):5457-65. PubMed ID: 9876115
[TBL] [Abstract][Full Text] [Related]
9. Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.
Pandey A; Volkots DL; Seroogy JM; Rose JW; Yu JC; Lambing JL; Hutchaleelaha A; Hollenbach SJ; Abe K; Giese NA; Scarborough RM
J Med Chem; 2002 Aug; 45(17):3772-93. PubMed ID: 12166950
[TBL] [Abstract][Full Text] [Related]
10. Potent and selective inhibitors of PDGF receptor phosphorylation. 2. Synthesis, structure activity relationship, improvement of aqueous solubility, and biological effects of 4-[4-(N-substituted (thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline derivatives.
Matsuno K; Nakajima T; Ichimura M; Giese NA; Yu JC; Lokker NA; Ushiki J; Ide S; Oda S; Nomoto Y
J Med Chem; 2002 Sep; 45(20):4513-23. PubMed ID: 12238930
[TBL] [Abstract][Full Text] [Related]
11. Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structure-activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaline, and cinnoline moieties.
Gomtsyan A; Bayburt EK; Schmidt RG; Zheng GZ; Perner RJ; Didomenico S; Koenig JR; Turner S; Jinkerson T; Drizin I; Hannick SM; Macri BS; McDonald HA; Honore P; Wismer CT; Marsh KC; Wetter J; Stewart KD; Oie T; Jarvis MF; Surowy CS; Faltynek CR; Lee CH
J Med Chem; 2005 Feb; 48(3):744-52. PubMed ID: 15689158
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical and mutational analysis of PDGF and PDGFR in desmoid tumours: is there a role for tyrosine kinase inhibitors in c-kit-negative desmoid tumours?
Liegl B; Leithner A; Bauernhofer T; Windhager R; Guelly C; Regauer S; Beham A
Histopathology; 2006 Dec; 49(6):576-81. PubMed ID: 17163842
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity studies on a library of potent calix[4]arene-based PDGF antagonists that inhibit PDGF-stimulated PDGFR tyrosine phosphorylation.
Zhou H; Wang DA; Baldini L; Ennis E; Jain R; Carie A; Sebti SM; Hamilton AD
Org Biomol Chem; 2006 Jun; 4(12):2376-86. PubMed ID: 16763682
[TBL] [Abstract][Full Text] [Related]
14. Antioxidants relieve phosphatase inhibition and reduce PDGF signaling in cultured VSMCs and in restenosis.
Kappert K; Sparwel J; Sandin A; Seiler A; Siebolts U; Leppänen O; Rosenkranz S; Ostman A
Arterioscler Thromb Vasc Biol; 2006 Dec; 26(12):2644-51. PubMed ID: 16990553
[TBL] [Abstract][Full Text] [Related]
15. Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. Part 4: structure-activity relationships for substituents on the quinazoline moiety of 4-[4-(N-substituted(thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline derivatives.
Matsuno K; Seishi T; Nakajima T; Ichimura M; Giese NA; Yu JC; Oda S; Nomoto Y
Bioorg Med Chem Lett; 2003 Sep; 13(18):3001-4. PubMed ID: 12941321
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of novel triazole, urea and thiourea derivatives of quinoline against Mycobacterium tuberculosis.
Upadhayaya RS; Kulkarni GM; Vasireddy NR; Vandavasi JK; Dixit SS; Sharma V; Chattopadhyaya J
Bioorg Med Chem; 2009 Jul; 17(13):4681-92. PubMed ID: 19457676
[TBL] [Abstract][Full Text] [Related]
17. Exploration of orally available calpain inhibitors 2: peptidyl hemiacetal derivatives.
Shirasaki Y; Nakamura M; Yamaguchi M; Miyashita H; Sakai O; Inoue J
J Med Chem; 2006 Jun; 49(13):3926-32. PubMed ID: 16789748
[TBL] [Abstract][Full Text] [Related]
18. New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
Colotta V; Catarzi D; Varano F; Capelli F; Lenzi O; Filacchioni G; Martini C; Trincavelli L; Ciampi O; Pugliese AM; Pedata F; Schiesaro A; Morizzo E; Moro S
J Med Chem; 2007 Aug; 50(17):4061-74. PubMed ID: 17665891
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and anti-HCV activity of thiourea compounds.
Kang IJ; Wang LW; Lee CC; Lee YC; Chao YS; Hsu TA; Chern JH
Bioorg Med Chem Lett; 2009 Apr; 19(7):1950-5. PubMed ID: 19251415
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of signal transduction: epidermal growth factor receptor family, vascular endothelial growth factor family, Kit, platelet-derived growth factor receptor, Ras.
Erman M
J BUON; 2007 Sep; 12 Suppl 1():S83-94. PubMed ID: 17935283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
